TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03827642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCl Intravenous (IV) Injection
Description: Participants received naloxone HCl IV injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCl Intravenous (IV) Injection
Description: Participants received naloxone HCl IV injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCl Intravenous (IV) Injection
Description: Participants received naloxone HCl IV injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCl Intravenous (IV) Injection
Description: Participants received naloxone HCl IV injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.
Study: NCT02032784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Description: Octreotide 100mg subcutaneous every 8 hours for 5 days

Intervention type: OTHER
Group type: OTHER
Intervention: No Octreotide
Description: No drug
Study: NCT03738215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine supplied in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine supplied in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied in capsules
Study: NCT03157791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone 180Mg Cap
Description: Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
Study: NCT02148627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658 (SC)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658 (IV)
Description: Administered as slow IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as slow IV infusion
Study: NCT03042637

Intervention type: DRUG
Intervention: Acthar Gel and Tacrolimus
Description: Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
Study: NCT01033071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil and hydrochlorothiazide
Description: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.
Study: NCT03208452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
Study: NCT00575302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f®: follitropin alpha
Description: Gonal-f®: follitropin alpha, administration of 300 U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f®: follitropin alpha
Description: Gonal-f®: follitropin alpha, administration of 450 U
Study: NCT04363814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bactek-R
Description: BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
Study: NCT00652132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Study: NCT00084253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/ Stavidine / Lamivudine
Description: Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir-Ritonavir/ Stavidine / Lamivudine
Description: Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
Study: NCT00177671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram, 10mg to 20mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram, 10mg to 20mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil, 5mg to 10mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine, 150mg to 300mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine, 150mg to 300mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Study: NCT03947034

Intervention type: DRUG
Intervention: Drugs inducing hyperammonemia
Description: Drugs susceptible to induce metabolic toxicities such as hyperammonemia
Study: NCT01765491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose polyethylene glycol
Description: Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning-only polyethylene glycol
Description: One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
Study: NCT01331902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Hyperemia with Adenosine Followed by Nicorandil
Description: Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Hyperemia with Nicorandil Followed by Adenosine
Description: Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
Study: NCT03247114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water, 300 ml at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature
Study: NCT03033498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: ABBV-951 administered by subcutaneous infusion.
Study: NCT00787254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefarnate
Description: Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
Study: NCT03557541

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sardine
Description: They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: They received a common T2D-preventive diet
Study: NCT04306783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-home sensor monitoring
Description: -Installed and maintained by Foresite Healthcare
Study: NCT02186691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT02649179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
Study: NCT01017926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triazolam
Description: Tablets, 0.25 mg, single-dose, 1 period of 3 three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
Study: NCT03666026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 MyChart R/R
Description: Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 MyChart R/R
Description: Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 MyChart R/R
Description: Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
Study: NCT03444090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon polypectomy
Description: For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size \>10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon polypectomy
Description: For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size \>10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
Study: NCT02598089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Seasonal Influenza Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of phosphate buffered saline
Study: NCT01612091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Messenger
Description: Monitoring Messenger prototype device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional tools
Description: Paper based records, screenshots of monitors and therapy devices
Study: NCT00308152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of 1 litre of normal saline before colonoscopy
Description: Prehydration with normal saline
Study: NCT02060747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinator-based post fracture program
Study: NCT06560814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline plus timed intercourse
Description: Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone plus timed intercourse
Description: Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
Study: NCT02181647

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Touches: Personal Safety Training for Children
Description: The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Touches: Personal Safety Training for Children
Description: The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
Study: NCT01188681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-016 and bendamustine
Description: TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg/kg TRU-016 and bendamustine
Description: TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg/kg TRU-016 and bendamustine
Description: TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
Study: NCT03247114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose, 50 grams in 300 ml water at room temperature
Study: NCT03060863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2. Executive Functioning
Description: Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3. Food Bias
Description: The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4. Emotion Regulation
Description: Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5. Future orientation
Description: Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present.